Investor Relations

Latest Financial Results

Q1 2024

Quarter Ended Mar 31, 2024

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

At Telomir Pharmaceuticals, we are committed to developing breakthrough science to address the root causes of difficult to treat diseases. By partnering with the brightest minds in science and healthcare, we have the potential to discover and develop ground-breaking treatments to bring about better health for patients and change the future of medicine.

Stock Snapshot

IR Contacts


Telomir Pharmaceuticals, Inc.
855 Wolfe St.
Ste 601.1
Baltimore, MD 21205
United States
T: 813-864-2558

Investor Relations

Phil Carlson
261 Madison Avenue, 9th Fl.
New York, NY 10016
T: 212-896-1233

Transfer Agent

6201 15th Avenue
Brooklyn, NY 11219
T: US 800-401-1957
T: Canada/US Virgin Islands 800-468-9716
T: Other International Access Codes